Cary Street Partners Investment Advisory LLC Sells 6,183 Shares of Danaher Co. (NYSE:DHR)

Cary Street Partners Investment Advisory LLC trimmed its holdings in Danaher Co. (NYSE:DHR) by 81.4% in the 4th quarter, HoldingsChannel reports. The firm owned 1,412 shares of the conglomerate’s stock after selling 6,183 shares during the quarter. Cary Street Partners Investment Advisory LLC’s holdings in Danaher were worth $327,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. BKM Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter worth $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher in the 4th quarter worth $29,000. OFI Invest Asset Management bought a new position in shares of Danaher during the 3rd quarter valued at about $30,000. Rakuten Securities Inc. purchased a new position in shares of Danaher during the fourth quarter valued at about $36,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher in the fourth quarter worth about $41,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,565 shares of company stock worth $26,641,364. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 0.1 %

Shares of NYSE DHR opened at $246.93 on Thursday. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a market cap of $182.90 billion, a P/E ratio of 41.85, a PEG ratio of 3.80 and a beta of 0.83. The firm has a 50-day simple moving average of $248.71 and a two-hundred day simple moving average of $231.90. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.36 EPS. Research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is 18.31%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DHR shares. TD Cowen increased their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Bank of America increased their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Royal Bank of Canada boosted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Barclays increased their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Finally, Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.